Mouton Y, Beuscart C, Leroy O, Ajana F, Charrel J
Service Universitaire des Maladies Infectieuses, CH Tourcoing, France.
Pathol Biol (Paris). 1991 Jan;39(1):34-7.
For the empiric management of community-acquired pneumonia, ciprofloxacin (750 mg b.i.d.) was compared with two antibiotics frequently used in this indication, i.e., amoxicillin + clavulanic acid and erythromycin. One hundred and forty-two patients were randomized in this prospective study. Among them, the 63 patients with bacteriologically documented disease were evaluated. Clinical recovery was achieved in 73.3% of patients in the ciprofloxacin group (22/30) versus 81.8% of patients in the amoxicillin + clavulanic acid or erythromycin group (27/33) (non-significant difference). Clinical failures seen with ciprofloxacin were found to be correlated with recovery of Streptococcus pneumoniae. Ciprofloxacin is effective in pneumonia but should be used only in cases where Streptococcus pneumoniae can be excluded as the causative agent.
为了对社区获得性肺炎进行经验性治疗,将环丙沙星(750毫克,每日两次)与常用于该适应症的两种抗生素,即阿莫西林+克拉维酸和红霉素进行了比较。在这项前瞻性研究中,142名患者被随机分组。其中,对63例有细菌学记录的疾病患者进行了评估。环丙沙星组73.3%的患者(22/30)实现了临床康复,而阿莫西林+克拉维酸或红霉素组为81.8%的患者(27/33)(无显著差异)。发现环丙沙星导致的临床失败与肺炎链球菌的恢复有关。环丙沙星对肺炎有效,但仅应在可以排除肺炎链球菌作为病原体的情况下使用。